Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A dose range finding study of PTI-NC-733 (fixed dose combination PTI-808, PTI-428 and PTI-801)

Next Previous
Trial Profile

A dose range finding study of PTI-NC-733 (fixed dose combination PTI-808, PTI-428 and PTI-801)

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 14 Nov 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs PTI NC 733 (Primary) ; PTI 808
  • Indications Cystic fibrosis
  • Focus Adverse reactions; Proof of concept

    • Most Recent Events

    • 14 Nov 2017 According to a Proteostasis Therapeutics media release, the company expects to initiate this trial in the first half of 2018.
    • 04 Jul 2017 New trial record
    • 29 Jun 2017 This trial is expected to begin in the end of 2017, according to a Proteostasis Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top